The NIHR Great Ormond Street Biomedical Research Centre (BRC) has been awarded £37 million in funding to drive forward translational research into rare diseases in children. The Centre is the only one of its kind in the UK dedicated to paediatric research.
Sir Michael Rake, currently Chairman of the BT Group plc, has been appointed as the new Chairman of Great Ormond Street Hospital for Children NHS Foundation Trust and will take up the position in November 2017.
Hundreds of children have been trained today as young lifesavers at Great Ormond Street Hospital (GOSH), learning vital cardiopulmonary resuscitation (CPR) skills as part of the national Restart A Heart Day.
GOSH BRC-supported researchers Dr Philippa Mills and Professor Peter Clayton, have identified a fault in the gene proline synthetase co-transcribed homolog (bacterial) (PROSC) in children with a rare strain of vitamin-B6 dependent epilepsy who are un-responsive to standard anti-epilepsy drugs.
A daily tablet has been shown to reduce the debilitating symptoms experienced by children with Multiple Sclerosis (MS) and cut the chance of relapse by 82%. There are currently no treatments specifically approved for adolescents with MS and this is the first time that an MS drug has been trialled specifically in young people.
This morning, the Chancellor of the Exchequer George Osborne visited Great Ormond Street Hospital (GOSH) to announce a new £800 million boost to biomedical research through the National Institute for Health Research (NIHR).
Walk down to Level 1 of the Frontage Building, and you'll discover the National Institute for Health Research (NIHR) Great Ormond Street Clinical Research Facility (CRF). This bright and colourful purpose-built centre provides a specialist ward area for children taking part in research studies.
The prospect of widespread access to a life-changing drug for children with a rare muscular disorder is a step closer today after the United States Food and Drug Administration (FDA) granted accelerated approval for a new medication.
This guideline describes the procedure which must be followed whenever a diagnosis of Mycobacterium Tuberculosis (M.TB) infection is suspected or confirmed, to optimally protect staff, patients and other visitors from risk of infection and assist in the care of the child with M.TB (not including Occupational Health policy).
Azathioprine is known as an immunosuppressant medicine. It is used at Great Ormond Street Hospital (GOSH) to treat certain types of chronic inflammatory conditions like systemic lupus erythematosus (SLE), vasculitis, eczema and Crohn’s disease.
This guideline is intended to supplement the resources found in the 'When a Child Dies' (WACD) purple box located in every ward, which gives detailed information on the care of a child after death and, additionally, the ongoing care and attention that the child's family will require (Rationale 1).